Torres Murillo, BertaRallón, NormaLoncá, MontserratDíaz Lorca, Maria AlbaAlós i Hernández, LlúciaMartínez Chamorro, Esteban JoséCruceta, AnnaArnaiz Gargallo, Juan AlbertoLeal, LornaLucero, ConstanzaLeón García, AgatheSánchez, MarceloNegredo, EugèniaClotet, Bonaventura, 1953-Gatell, José M.Benito, José M.García Alcaide, Felipe2017-02-102017-02-102014-05-020889-2229https://hdl.handle.net/2445/106786CD4+ count increase has been reported to be different with lopinavir/r (LPV/r) and efavirenz (EFV)-containing regimens. The different effect of these two regimens on other immune function parameters and the relationship with the gain of CD4+ count have not been assessed in a randomized clinical trial. Fifty antiretroviral treatment (cART) naïve HIV-infected individuals were randomized to receive LPV/r or EFV both with tenofovir/emtricitabine for 48 weeks. A substudy of immunological function restoration was performed in 22 patients (LPV/r n=10 and EFV n=12). Activation, thymic function, apoptosis, senescence, exhaustion, Treg cells, interleukin (IL)-7-receptor/IL-7 system, thymic volume, and lymphoid tissue fibrosis were evaluated at baseline and at week 48. Both groups experienced a CD4+ count increase that was higher in the EFV group (ΔCD4+ 88 vs. 315 cells/μl LPV/r vs. EFV, respectively, p<0.001). Despite this difference in CD4+ gain, the change in other immune function parameters was similar in both treatment groups. Most of parameters evaluated tended to normalize after 48 weeks of cART. A significant decrease in levels of activation, senescence, exhaustion, and apoptosis on CD4+ and CD8+ T cells (p<0.001 for all) and a significant increase in markers of thymic function, IL-7 receptor, and in the levels of central memory CD4+ T cells and naive subsets of CD8+ T cells (p<0.001 for all) with respect to baseline values were observed without any difference between groups. These data indicate that the differences in CD4+ gain with different cART regimens are not immunologically meaningful and might explain the similar clinical efficacy of these regimens.9 p.application/pdfeng(c) Mary Ann Liebert, 2014VIH (Virus)Sistema immunològicAntiretroviralsHIV (Viruses)Immune systemAntiretroviral agentsinfo:eu-repo/semantics/article6355772017-02-10info:eu-repo/semantics/openAccess24380397